413 related articles for article (PubMed ID: 28814832)
1. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma.
Hrynyk M; Ellis JP; Haxho F; Allison S; Steele JA; Abdulkhalek S; Neufeld RJ; Szewczuk MR
Drug Des Devel Ther; 2015; 9():4573-86. PubMed ID: 26309402
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Jaidev LR; Krishnan UM; Sethuraman S
Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():40-7. PubMed ID: 25492170
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
Devulapally R; Foygel K; Sekar TV; Willmann JK; Paulmurugan R
ACS Appl Mater Interfaces; 2016 Dec; 8(49):33412-33422. PubMed ID: 27960411
[TBL] [Abstract][Full Text] [Related]
5. Delivery of doxorubicin and paclitaxel from double-layered microparticles: The effects of layer thickness and dual-drug vs. single-drug loading.
Lee WL; Guo WM; Ho VHB; Saha A; Chong HC; Tan NS; Tan EY; Loo SCJ
Acta Biomater; 2015 Nov; 27():53-65. PubMed ID: 26340886
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
7. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Aggarwal S; Yadav S; Gupta S
J Biomed Nanotechnol; 2011 Feb; 7(1):137-8. PubMed ID: 21485840
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.
Papa AL; Basu S; Sengupta P; Banerjee D; Sengupta S; Harfouche R
BMC Cancer; 2012 Sep; 12():419. PubMed ID: 22998550
[TBL] [Abstract][Full Text] [Related]
9. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
10. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
Khare V; Kour S; Alam N; Dubey RD; Saneja A; Koul M; Gupta AP; Singh D; Singh SK; Saxena AK; Gupta PN
Int J Pharm; 2014 Aug; 470(1-2):51-62. PubMed ID: 24810239
[TBL] [Abstract][Full Text] [Related]
12. UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Neutsch L; Wambacher M; Wirth EM; Spijker S; Kählig H; Wirth M; Gabor F
Int J Pharm; 2013 Jun; 450(1-2):163-76. PubMed ID: 23628404
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer.
Li S; Li X; Ding J; Han L; Guo X
Drug Des Devel Ther; 2019; 13():1271-1280. PubMed ID: 31114163
[No Abstract] [Full Text] [Related]
14. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
[TBL] [Abstract][Full Text] [Related]
15. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Wang Y; Kuramitsu Y; Kitagawa T; Tokuda K; Baron B; Akada J; Nakamura K
Target Oncol; 2015 Dec; 10(4):575-81. PubMed ID: 25940934
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
17. Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients.
Xiao Y; Gao Y; Li F; Deng Z
Drug Deliv; 2020 Dec; 27(1):1491-1500. PubMed ID: 33100060
[TBL] [Abstract][Full Text] [Related]
18. Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Liu D; Zhang W; Liu X; Qiu R
Drug Deliv; 2021 Dec; 28(1):776-786. PubMed ID: 33866910
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
20. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Martín-Banderas L; Sáez-Fernández E; Holgado MÁ; Durán-Lobato MM; Prados JC; Melguizo C; Arias JL
Int J Pharm; 2013 Feb; 443(1-2):103-9. PubMed ID: 23299085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]